Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

MolMed S.p.A. (MLMD.MI)

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed’s is also developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. The product, whose innovative spacer incorporated in the CAR protein received in May 2019 the confirmation of grant, is potentially effective also in several epithelial solid tumors. MolMed is also developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. *

 

Period Start 1996-01-01 established
  Group Asahi Glass (AGC) (Group)
  Predecessor San Raffaele Scientific University Institute
Products Industry gene therapy
  Industry 2 cell therapy
Persons Person Palmisano, Riccardo (InnovaVector 202210– before MolMed 201606 CEO)
  Person 2 Calabrese, Salvatore (MolMed 201809– CFO before Gentium CFO 2005–2014 + Novopharma SpA + PriceWaterhouseCoopers)
     
Region Region Milano (Milan)
  Country Italy
  Street 58 via Olgettina
  City 20132 Milan
  Tel +39-02-21277-1
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2020-03-17)
  Currency EUR
  Annual sales 36,272,000 (revenues, operating, total (2019) 2019-12-31)
  Profit -427,000 (2019-12-31)
  Cash 9,904,000 (2019-12-31)
     
    * Document for »About Section«: MolMed S.p.A.. (10/10/19). "Press Release: MolMed Informs on Its Decision to Withdraw the Conditional Marketing Authorization of Zalmoxis". Milan.
     
   
Record changed: 2024-03-25

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Asahi Glass (AGC) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top